• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals Inc (NQ: MDGL )

    279.54 +20.20 (+7.79%)
    Streaming Delayed Price Updated: 9:38 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Madrigal Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 Next >
    3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
    NASH treatments are projected to be one of the most sought-after indications in the coming years. 
    Via The Motley Fool
    Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
    NASH is a surprisingly common ailment, and the first treatments are on the way. 
    Via The Motley Fool
    Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
    Novo Nordisk received some good news in a recent physician survey. 
    Via The Motley Fool
    Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
    Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
    Via Investor's Business Daily
    Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
    Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
    Via Benzinga
    Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
    Two key tailwinds appear to be lifting the stock today. 
    Via The Motley Fool
    Analyst Expectations for Madrigal Pharmaceuticals's Future
    Via Benzinga
    Why Madrigal Pharmaceuticals Stock Is Slumping Today
    The biotech's shares briefly plunged following its 2023 Q1 earnings report. 
    Via The Motley Fool
    Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
    Via Benzinga
    2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
    Recent moves to the upside could be the beginning of a much larger bull run. 
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading
    Via Investor Brand Network
    Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
    Via Investor Brand Network
    Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
    The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
    Via Investor's Business Daily
    Why These 3 Nasdaq Stocks Buckled Today
    The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
    Via The Motley Fool
    Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
    Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    3 Biotechs That Might Get Bought Out in 2023
    Biotech is expected to be a hotbed of mergers and acquisitions this year. 
    Via The Motley Fool
    Why Madrigal Pharmaceuticals Stock Gained 20% This Week
    Two key tailwinds fueled a surge in the biotech's share price this week. 
    Via The Motley Fool
    Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
    Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
    Via Benzinga
    Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
    Shares are closing in on a buy point after retaking their 50-day moving average. 
    Via Investor's Business Daily
    Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
    Via Investor Brand Network
    5 Best Stocks to Buy in April
    These powerful trends should yield stellar returns for investors in April and beyond. 
    Via The Motley Fool
    Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
    Viking Therapeutics stock might in the midst of a historic run. 
    Via The Motley Fool
    Is Viking Therapeutics a Smart Buy on the Dip?
    The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
    Via The Motley Fool
    Want Diversified Upside in Biotechnology? Check out LABU
    Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
    Via MarketBeat
    Topics ETFs Stocks
    Exposures US Equities
    The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
    To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
    Via InvestorPlace
    Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
    Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals. 
    Via Investor's Business Daily
    1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030
    This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.